Improving Oral Bioavailability Prediction With Human Models
Fill out the form below, and we shall send your colleague an invitation to the "Improving Oral Bioavailability Prediction With Human Models" event.
Predicting human oral drug exposure remains a significant challenge in preclinical drug development. Intestinal absorption, first-pass metabolism, enzyme variability, and transporter-mediated interactions can all influence systemic exposure, yet conventional models may not fully capture how these processes combine.
This webinar will explore validation data from an integrated primary human Gut/Liver microphysiological system (MPS) that enables intestinal and hepatic contributions to drug disposition to be assessed independently and together.
Attendees will see how the model predicts oral bioavailability, captures CYP2D6-dependent variability, and identifies clinically relevant CYP3A4- and transporter-mediated drug-drug interactions (DDIs). Learn how MPS-derived data can also be translated into quantitative ADME parameters and incorporated into physiologically based pharmacokinetic (PBPK) models to support prediction of clinical pharmacokinetics.
Attend this webinar to:
- Evaluate oral absorption, first-pass metabolism, and bioavailability using an integrated human Gut/Liver MPS
- Distinguish intestinal and hepatic contributions to drug disposition and DDIs
- Review validation data for CYP2D6-dependent variability, CYP3A4, and transporter-mediated DDIs
- Translate MPS-derived data into quantitative ADME parameters for PBPK prediction of clinical pharmacokinetics
